Air Pollution Tied to Poor Outcomes in Lung Transplant

Share this content:
Air Pollution Tied to Poor Outcomes in Lung Transplant
Air Pollution Tied to Poor Outcomes in Lung Transplant

WEDNESDAY, Sept. 30, 2015 (HealthDay News) -- Living near busy roads with high levels of air pollution raises lung transplant patients' risk of organ rejection and death, but use of macrolides may lower that risk, according to a study presented Tuesday at the annual meeting of the European Respiratory Society, held from Sept. 26 to 30 in Amsterdam.

Researchers examined data gathered from 5,707 lung transplant patients in 10 European countries between 1987 and 2013. The investigators found that patients who lived in areas where air pollution was above maximum levels recommended by the World Health Organization (WHO) were 10 percent more likely to die than those in areas with lower levels of pollution.

During the nearly six years of follow-up, 45.2 percent of the patients died and 47.1 percent developed chronic organ rejection. About 62 percent of patients took macrolides at some point. Chronic organ rejection occurred in 61.5 percent of those taking macrolides. Nearly 30 percent of patients taking macrolides died, compared with 54.5 percent of those who did not take macrolides.

"Short- and long-term exposure to air pollution has been linked to an increase in deaths from respiratory diseases, particularly among vulnerable populations," study author David Ruttens, M.D., said in a European Lung Foundation news release. Ruttens is a specialist in respiratory medicine at the University of Leuven in Belgium. If air pollution were reduced to below the level recommended by the WHO, Ruttens said, "there would be a 9.9 percent reduction in deaths among lung transplant patients who were not taking macrolides, and 6.4 percent reduction among all patients, regardless of whether or not they were taking macrolides."

Abstract No. 3270
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »